Research

Mixed

Individualized Virtual Integrative Medicine (IVIM) protocol combined with tirzepatide results in significant weight loss (mean -52.28 lbs at 52 weeks) and high treatment adherence (99.36% achieving >5% weight loss) compared to standard care models.

If you have obesity (BMI >= 30) and are starting tirzepatide, consider a program that offers flexible dosing and regular telehealth support. This approach allows you to adjust your dose based on side effects and progress, rather than following a rigid schedule. Most patients in this study lost significant weight (over 20 lbs on average at 52 weeks) without needing the highest dose, and compounded versions worked just as well as branded ones. The key is consistent support and personalized adjustments.

ModerateSupportsMEDIUM confidence
Patients completing 52-weeks of tirzepatide therapy on the IVIM protocol experienced significant weight loss with a high level of treatment adherence and program utilization.
Jessica Duncan et al. · Obesity Pillars · 2025

Why this rating

Retrospective cohort study, not randomized controlled trial; potential selection bias and self-reported data.

Source

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol

Jessica Duncan et al. · Obesity Pillars · 2025

DOI 10.1016/j.obpill.2025.100236

cohort · n=1166
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →